Medindia

X

DATATRAK International Launches Innovative, Interactive Educational Webcast Series

Wednesday, December 19, 2007 General News J E 4
Advertisement
CLEVELAND, Dec. 18 DATATRAK International, Inc.(Nasdaq: DATA), a technology and services company focused on global eClinicalsolutions for the clinical trials industry, today reported that it haslaunched a new initiative involving a continuous series of educational andinnovative webcasts. Delivered via email approximately twice a month, andalso residing on the Company's website in a library format for convenientviewing, 'eClinical Dialogues' will feature DATATRAK professionals discussingcritical issues and advancements that affect the use of technology in today'sworldwide clinical trials market. The targeted audience for these webcastsincludes the Company's customer and investor markets, as the topics coveredwill be informative and applicable to both constituencies.

"Our goal is to provide timely, relevant topics of interest toprofessionals involved in all aspects of clinical trials and to be able todeliver the messages in an innovative and efficient format," said Dr. JeffreyA. Green, President and Chief Executive Officer, DATATRAK International Inc."This new webcast venue is unique in our market, allowing us to shareinformation in a medium that is both interactive and convenient. Viewers cansimply click on a link in the email or visit our website for a completelibrary of topics."

Webcast content will be updated regularly and will include information onsome of the following issues:

In addition, these webcasts will also be used to disseminate breakingDATATRAK news on an as-needed basis as with the recent announcement of therelationship between NTT DATA Corporation of Japan and DATATRAK.

The DATATRAK eClinical Dialogues can be viewed or replayed at any time.Other interactive features include the option to submit questions, comments orsuggestions for ongoing or future expansions on any topic. Please visitwww.datatrak.net to view current webcasts, or for additional information.

DATATRAK International, Inc. is a worldwide technology company focused onthe provision of multi-component eClinical solutions and related services forthe clinical trials industry. The Company delivers a complete portfolio ofsoftware products that were created in order to accelerate clinical researchdata from investigative sites to clinical trial sponsors and ultimately theFDA, faster and more efficiently than manual methods or loosely integratedtechnologies. DATATRAK's eClinical software suite can be deployed worldwidethrough an ASP offering or in a licensed Enterprise Transfer model that fullyempowers its clients. The DATATRAK software suite and its earlier versionshave successfully supported hundreds of international clinical trialsinvolving thousands of clinical research sites and encompassing tens ofthousands of patients in 59 countries. DATATRAK International, Inc.'s productsuite has been utilized in some aspect of the clinical development of 17 drugsand devices that have received regulatory approval from either the UnitedStates Food and Drug Administration or counterpart European bodies. DATATRAKInternational, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, andBryan, Texas. Its common stock is listed on the NASDAQ Stock Market under theticker symbol "DATA". Visit the DATATRAK International, Inc. web site atwww.datatrak.net.

Except for the historical information contained in this press release, thestatements made in this release are forward-looking statements. Theseforward-looking statements are made based on management's expectations andbeliefs concerning future events impacting the Company and are subject touncertainties and factors (including those specified below) which aredifficult to predict and, in many instances, are beyond the control of theCompany. Factors that may cause actual results to differ materially from thosein the forward-looking statements include the limited operating history onwhich the Company's performa
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cyberonics Licenses Obesity-Related Patents
S
Survey of More than 600 Patients Treated with Trac...